{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:54:01Z","timestamp":1789610041537,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T00:00:00Z","timestamp":1639785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T00:00:00Z","timestamp":1639785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Urovant Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s12325-021-01972-8","type":"journal-article","created":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T12:02:37Z","timestamp":1639828957000},"page":"959-970","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR"],"prefix":"10.1007","volume":"39","clinical-trial-number":[{"clinical-trial-number":"nct03492281","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jeffrey","family":"Frankel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Staskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susann","family":"Varano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kennelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane K.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt T.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael A.","family":"Jankowich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Shortino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Paul N.","family":"Mudd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia J.","family":"Girman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,18]]},"reference":[{"issue":"1","key":"1972_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/nau.20798","volume":"29","author":"BT Haylen","year":"2010","unstructured":"Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4\u201320.","journal-title":"Neurourol Urodyn"},{"key":"1972_CR2","doi-asserted-by":"crossref","unstructured":"Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline. American Urological Association; 2019.","DOI":"10.1097\/JU.0000000000000309"},{"issue":"5","key":"1972_CR3","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.urology.2010.08.039","volume":"77","author":"KS Coyne","year":"2011","unstructured":"Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081\u20137.","journal-title":"Urology"},{"issue":"4","key":"1972_CR4","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/nau.23094","volume":"36","author":"A Rantell","year":"2017","unstructured":"Rantell A, Cardozo L, Khullar V. Personal goals and expectations of OAB patients in the UK. Neurourol Urodyn. 2017;36(4):1194\u2013200.","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"1972_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/1359105314522084","volume":"21","author":"D Kinsey","year":"2016","unstructured":"Kinsey D, Pretorius S, Glover L, Alexander T. The psychological impact of overactive bladder: a systematic review. J Health Psychol. 2016;21(1):69\u201381.","journal-title":"J Health Psychol"},{"issue":"4","key":"1972_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1524-4733.2004.74008.x","volume":"7","author":"KS Coyne","year":"2004","unstructured":"Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004;7(4):455\u201363.","journal-title":"Value Health"},{"issue":"9","key":"1972_CR7","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1111\/j.1464-410X.2010.10013.x","volume":"108","author":"KS Coyne","year":"2011","unstructured":"Coyne KS, Sexton CC, Kopp ZS, Ebel-Bitoun C, Milsom I, Chapple C. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int. 2011;108(9):1459\u201371.","journal-title":"BJU Int"},{"issue":"3","key":"1972_CR8","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s12325-019-0880-8","volume":"36","author":"KM Johnston","year":"2019","unstructured":"Johnston KM, Walker DR, Lakzadeh P. Characterizing the health-related quality of life burden of overactive bladder using disease-specific patient-reported outcome measures: a systematic literature review. Adv Ther. 2019;36(3):548\u201362.","journal-title":"Adv Ther"},{"key":"1972_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.urology.2016.07.013","volume":"98","author":"HH Lai","year":"2016","unstructured":"Lai HH, Rawal A, Shen B, Vetter J. The relationship between anxiety and overactive bladder or urinary incontinence symptoms in the clinical population. Urology. 2016;98:50\u20137.","journal-title":"Urology"},{"issue":"1","key":"1972_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12894-016-0179-x","volume":"16","author":"HH Lai","year":"2016","unstructured":"Lai HH, Shen B, Rawal A, Vetter J. The relationship between depression and overactive bladder\/urinary incontinence symptoms in the clinical OAB population. BMC Urol. 2016;16(1):60.","journal-title":"BMC Urol"},{"issue":"6A Suppl","key":"1972_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0090-4295(97)00599-2","volume":"50","author":"RA Appell","year":"1997","unstructured":"Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology. 1997;50(6A Suppl):90\u20139.","journal-title":"Urology"},{"issue":"7","key":"1972_CR12","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/j.1464-410X.2005.05454.x","volume":"95","author":"C Chapple","year":"2005","unstructured":"Chapple C, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int. 2005;95(7):993\u20131001.","journal-title":"BJU Int"},{"issue":"6","key":"1972_CR13","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","volume":"189","author":"VW Nitti","year":"2013","unstructured":"Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186\u201393.","journal-title":"J Urol"},{"issue":"7","key":"1972_CR14","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/ijcp.12194","volume":"67","author":"VW Nitti","year":"2013","unstructured":"Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013;67(7):619\u201332.","journal-title":"Int J Clin Pract"},{"issue":"5","key":"1972_CR15","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.eururo.2016.04.033","volume":"70","author":"CR Chapple","year":"2016","unstructured":"Chapple CR, Kelleher CJ, Evans CJ, et al. A narrative review of patient-reported outcomes in overactive bladder: what is the way of the future? Eur Urol. 2016;70(5):799\u2013805.","journal-title":"Eur Urol"},{"issue":"2 Suppl","key":"1972_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.urology.2006.05.045","volume":"68","author":"L Brubaker","year":"2006","unstructured":"Brubaker L, Chapple C, Coyne KS, Kopp Z. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology. 2006;68(2 Suppl):3\u20138.","journal-title":"Urology"},{"issue":"5","key":"1972_CR17","doi-asserted-by":"publisher","first-page":"e13937","DOI":"10.1111\/ijcp.13937","volume":"75","author":"J Frankel","year":"2021","unstructured":"Frankel J, Varano S, Staskin D, Shortino D, Jankowich R, Mudd PN Jr. Vibegron improves quality-of-life measures in patients with overactive bladder: patient-reported outcomes from the EMPOWUR study. Int J Clin Pract. 2021;75(5):e13937.","journal-title":"Int J Clin Pract"},{"issue":"2","key":"1972_CR18","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/j.1464-410X.2008.07523.x","volume":"102","author":"P Abrams","year":"2008","unstructured":"Abrams P, Kelleher C, Huels J, Quebe-Fehling E, Omar MA, Steel M. Clinical relevance of health-related quality of life outcomes with darifenacin. BJU Int. 2008;102(2):208\u201313.","journal-title":"BJU Int"},{"issue":"1","key":"1972_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12955-018-0892-0","volume":"16","author":"S Herschorn","year":"2018","unstructured":"Herschorn S, Staskin D, Tu LM, et al. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER). Health Qual Life Outcomes. 2018;16(1):69.","journal-title":"Health Qual Life Outcomes"},{"key":"1972_CR20","volume-title":"Full Prescribing Information","author":"GEMTESA\u00ae (vibegron)","year":"2020","unstructured":"GEMTESA\u00ae (vibegron). Full Prescribing Information. Irvine: Urovant Sciences; 2020."},{"issue":"2","key":"1972_CR21","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/JU.0000000000000807","volume":"204","author":"D Staskin","year":"2020","unstructured":"Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020;204(2):316\u201324.","journal-title":"J Urol"},{"issue":"4","key":"1972_CR22","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/S0090-4295(02)02505-0","volume":"61","author":"JS Brown","year":"2003","unstructured":"Brown JS, McNaughton KS, Wyman JF, et al. Measurement characteristics of a voiding diary for use by men and women with overactive bladder. Urology. 2003;61(4):802\u20139.","journal-title":"Urology"},{"issue":"2","key":"1972_CR23","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/1471-0528.12069","volume":"120","author":"DG Tincello","year":"2013","unstructured":"Tincello DG, Owen RK, Slack MC, Abrams KR. Validation of the Patient Global Impression scales for use in detrusor overactivity: secondary analysis of the RELAX study. BJOG. 2013;120(2):212\u20136.","journal-title":"BJOG"},{"issue":"2","key":"1972_CR24","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.eururo.2018.10.006","volume":"75","author":"HD Mitcheson","year":"2019","unstructured":"Mitcheson HD, Samanta S, Muldowney K, et al. Vibegron (RVT-901\/MK-4618\/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. Eur Urol. 2019;75(2):274\u201382.","journal-title":"Eur Urol"},{"issue":"1","key":"1972_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2307\/2530643","volume":"41","author":"S Greenland","year":"1985","unstructured":"Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics. 1985;41(1):55\u201368.","journal-title":"Biometrics"},{"issue":"6","key":"1972_CR26","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s11136-011-0003-8","volume":"21","author":"JM Norquist","year":"2012","unstructured":"Norquist JM, Girman C, Fehnel S, DeMuro-Mercon C, Santanello N. Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration. Qual Life Res. 2012;21(6):1013\u201320.","journal-title":"Qual Life Res"},{"key":"1972_CR27","doi-asserted-by":"crossref","unstructured":"Pinto CA, Norquist J, Liao J, Frenkl T, Girman C. Understanding MID for micturition frequency, a pivotal endpoint for OAB studies. Presented at: ISPOR 19th Annual International Meeting; May 31\u2013June 4, 2014; Montreal, QC, Canada.","DOI":"10.1016\/j.jval.2014.03.1713"},{"key":"1972_CR28","unstructured":"US Department of Health and Human Services. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Silver Spring, MD: US Department of Health and Human Services; 2009."},{"key":"1972_CR29","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/1477-7525-11-200","volume":"11","author":"K Desroziers","year":"2013","unstructured":"Desroziers K, Aball\u00e9a S, Maman K, Nazir J, Odeyemi I, Hakimi Z. Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder. Health Qual Life Outcomes. 2013;11:200.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"1972_CR30","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/j.1742-1241.2008.01778.x","volume":"62","author":"KS Coyne","year":"2008","unstructured":"Coyne KS, Elinoff V, Gordon DA, et al. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. Int J Clin Pract. 2008;62(6):925\u201331.","journal-title":"Int J Clin Pract"},{"issue":"2","key":"1972_CR31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1742-1241.2010.02532.x","volume":"65","author":"RD Crosby","year":"2011","unstructured":"Crosby RD, Mathias SD, Marshall TS. Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. Int J Clin Pract. 2011;65(2):211\u20138.","journal-title":"Int J Clin Pract"},{"issue":"7","key":"1972_CR32","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/nau.21065","volume":"30","author":"Y Kubota","year":"2011","unstructured":"Kubota Y, Kojima Y, Shibata Y, Imura M, Kohri K, Sasaki S. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug. Neurourol Urodyn. 2011;30(7):1309\u201314.","journal-title":"Neurourol Urodyn"},{"key":"1972_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1477-7525-7-13","volume":"7","author":"PE Van Kerrebroeck","year":"2009","unstructured":"Van Kerrebroeck PE, Kelleher CJ, Coyne KS, Kopp Z, Brodsky M, Wang JT. Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health Qual Life Outcomes. 2009;7:13.","journal-title":"Health Qual Life Outcomes"},{"key":"1972_CR34","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00192-005-1300-y","volume":"16","author":"L Brubaker","year":"2005","unstructured":"Brubaker L, Shull B. EGGS for patient-centered outcomes. Int Urogynecol J Pelvic Floor Dysfunct. 2005;16:171\u20133.","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"issue":"7","key":"1972_CR35","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/j.1742-1241.2012.02951.x","volume":"66","author":"KS Lee","year":"2012","unstructured":"Lee KS, Lee YS, Kim JC, Seo JT, Lee JZ, Choo MS. Patient-reported goal achievement after antimuscarinic treatment in patients with overactive bladder symptoms. Int J Clin Pract. 2012;66(7):663\u201370.","journal-title":"Int J Clin Pract"},{"issue":"2","key":"1972_CR36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1742-1241.2007.01652.x","volume":"62","author":"MS Choo","year":"2008","unstructured":"Choo MS, Doo CK, Lee KS. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study). Int J Clin Pract. 2008;62(2):191\u20136.","journal-title":"Int J Clin Pract"},{"key":"1972_CR37","doi-asserted-by":"crossref","unstructured":"Mostafaei H, Janisch F, Mori K, et al. Placebo response in patients with oral therapy for overactive bladder: a systematic review and meta-analysis. Eur Urol Focus. 2021 (Epub ahead of print).","DOI":"10.1016\/j.euf.2021.02.005"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01972-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01972-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01972-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T12:57:28Z","timestamp":1699966648000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01972-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,18]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1972"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01972-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,18]]},"assertion":[{"value":"23 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}